10x Genomics, Inc. (LON:0A88)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 8.43B +655.6% |
| Revenue (ttm) | 464.97M -4.3% |
| Net Income | -56.62M |
| EPS | -0.44 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,026 |
| Open | 84.50 |
| Previous Close | 81.97 |
| Day's Range | 80.75 - 88.00 |
| 52-Week Range | 11.17 - 88.00 |
| Beta | 2.08 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 4, 2026 |
About 10x Genomics
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium p... [Read more]
Financial Performance
In 2025, 10x Genomics's revenue was $642.82 million, an increase of 5.25% compared to the previous year's $610.79 million. Losses were -$43.54 million, -76.16% less than in 2024.
Financial numbers in USD Financial StatementsNews
10x Genomics partners with Korea-based Lunit for AI-enabled pathology analysis
10x Genomics (TXG) will incorporate Lunit’s AI-powered pathology platform, Lunit SCOPE IO, into its oncology biomarker discovery workflow. Lunit SCOPE IO will be used to analyze Hematoxylin and Eosin ...
Lunit Announces Collaboration with 10x Genomics to Integrate AI-Enabled Pathology Analysis with Spatial Molecular Data for Oncology Clinical Research
10x Genomics, a leader in single-cell and spatial biology, to combine its spatial biology technologies with Lunit's AI-powered H&E pathology analysis to advance oncology biomarker discovery SEOUL, Sou...
10x Genomics assumed with a Neutral at UBS
UBS analyst Doug Schenkel assumed coverage of 10x Genomics (TXG) with a Neutral rating and $68 price target The firm initiated and resumed 25 life science and diagnostics tools companies.
10x Genomics initiated with a Sector Perform at RBC Capital
RBC Capital initiated coverage of 10x Genomics (TXG) with a Sector Perform rating and $70 price target The firm has a constructive view on the Atera launch and spatial opportunity.
10x Genomics reports patent infringement win against Parse Biosciences
10x Genomics (TXG) announced that a jury in the U.S. District Court for the District of Delaware found that Parse Biosciences, now a subsidiary of Qiagen (QGEN), willfully infringed three…
10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences
Jury finds Parse willfully infringed Scale Biosciences' patents and rejects Parse's invalidity challenge PLEASANTON, Calif., Aug. 28, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life sc...
10x Genomics price target raised to $65 from $50 at Stephens
Stephens analyst Mason Carrico raised the firm’s price target on 10x Genomics (TXG) to $65 from $50 and keeps an Overweight rating on the shares. The firm is updating its…
10x Genomics price target raised to $60 from $50 at Canaccord
Canaccord analyst Kyle Mikson raised the firm’s price target on 10x Genomics (TXG) to $60 from $50 and keeps a Buy rating on the shares. The firm met with management…
10x Genomics price target raised to $47 from $42 at Piper Sandler
Piper Sandler raised the firm’s price target on 10x Genomics (TXG) to $47 from $42 and keeps a Neutral rating on the shares following quarterly results. The firm cites updated…
10x Genomics price target raised to $40 from $37 at Morgan Stanley
Morgan Stanley raised the firm’s price target on 10x Genomics (TXG) to $40 from $37 and keeps an Equal Weight rating on the shares.
10x Genomics price target raised to $50 from $25 at Stifel
Stifel raised the firm’s price target on 10x Genomics (TXG) to $50 from $25 and keeps a Buy rating on the shares.
10x Genomics price target raised to $50 from $45 at Citi
Citi analyst Brendan Digan raised the firm’s price target on 10x Genomics (TXG) to $50 from $45 and keeps a Neutral rating on the shares.
10x Genomics Earnings Call Transcript: Q2 2026
Q2 revenue grew 3% YoY (excluding settlements), driven by strong consumables growth and exceptional demand for the new Atera platform, though instrument sales declined. Full-year guidance was raised, with Atera orders exceeding shipment capacity and AI adoption fueling demand across customer segments.
10x Genomics Earnings release: Q2 2026
10x Genomics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
10x Genomics Quarterly report: Q2 2026
10x Genomics has published its Q2 2026 quarterly earnings report on August 6, 2026.
10x Genomics reports Q2 EPS (14c), consensus (2c)
Reports Q2 revenue $151.0M, consensus $146.61M. “The story of the quarter was the extraordinary customer response to Atera. We are highly encouraged by the engagement across the research ecosystem and...
10x Genomics raises 2026 revenue view to $610M-$630M from $600M-$625M
2026 revenue consensus $614.06M.
10x Genomics Reports Second Quarter 2026 Financial Results
PLEASANTON, Calif., Aug. 6, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today reported financi...
10x Genomics announces research collaboration with Lausanne University Hospital
10x Genomics (TXG) announced a research collaboration with Lausanne University Hospital, or CHUV, one of Switzerland’s leading academic medical centers, to advance research in diagnostic applications ...
10x Genomics and Lausanne University Hospital Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies for Cancer Care
Collaboration aims to identify biomarkers predictive of treatment response across multiple cancer types using 10x's single cell and spatial platforms PLEASANTON, Calif., July 29, 2026 /PRNewswire/ -- ...
10x Genomics price target raised to $40 from $23 at Leerink
Leerink raised the firm’s price target on 10x Genomics (TXG) to $40 from $23 and keeps a Market Perform rating on the shares. The firm cites higher industry multiples. Key…
10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026
PLEASANTON, Calif., July 15, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, announced it will rep...
10x Genomics price target raised to $47 from $25 at TD Cowen
TD Cowen raised the firm’s price target on 10x Genomics (TXG) to $47 from $25 and keeps a Hold rating on the shares. The firm adjusted targets in the tools…
10x Genomics price target raised to $50 from $32 at Canaccord
Canaccord analyst Kyle Mikson raised the firm’s price target on 10x Genomics (TXG) to $50 from $32 and keeps a Buy rating on the shares. The firm updated its model…